

# Press Release



## **Announcing the conclusion of the license agreement for Ulipristal acetate regarding gynecological benign disorders and establishing the new contact agreement regarding intellectual property rights.**

---

**TOKYO, July 31st, 2018** – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced the conclusion of the license agreement for "Ulipristal acetate" (development code: CDB-2914) within the therapeutic area of obstetrics and gynecology, which was in-licensed from Laboratoire HRA Pharma (Head Office: France, hereinafter "HRA") in May of 2011. In addition, as of today, a new contract agreement has been reached regarding the intellectual property rights of Ulipristal acetate within Japan.

As a result of the agreement, ASKA will receive the exclusive rights for intellectual property related to gynecological disorders including uterine fibroids and the related trademarks of Ulipristal acetate.

Also, ASKA will pay a fee upon the contract agreement as well as a payment upon receiving the approval for manufacture and marketing for the first-time.

Following the launch of Ulipristal acetate, the double-digit percent royalty payments will be lost. The details related to the contract agreement and payment will not be disclosed.

The current matter will not have any impact on the development which ASKA has been conducting a Phase 3 clinical study within Japan, and as ASKA is a specialty pharma in Internal medicine, Obstetrics and gynecology, and Urology, we consider Ulipristal acetate to be a very important agent that will fulfill the medical needs in obstetrics and gynecology.

The impact of the payments due to this contract agreement is currently being determined. If any information comes to light that need to be disclosed, it will done in a timely manner.

### [Reference]

Located in Paris, France, Laboratoire HRA Pharma provides medications, devices, and support services to healthcare professionals and patients worldwide in niche healthcare areas. Especially targeting the therapeutic gaps in reproductive disorders and endocrine disorders as well as providing marketing activities, educational programs, and provide appropriate understanding of disorders and medication use. In addition, by establishing various branches across Europe and building a wide network for research, manufacturing, and distribution as well as with non-profit organizations, HRA contributes to improving medical care as well as patient needs in more than 50 countries.

For more information, please visit [www.hra-pharma.com](http://www.hra-pharma.com)